Fig. 6. ARVAC CG booster induces significant increase of Th1-predominant cell response measured by IFN-γ and IL-4 ELISpot after restimulation of PBMCs with RBD spanning peptide pool.
Before booster administration (d1) and after 28 days (d28) of administration of ARVAC CG 25 μg (a) or 50 μg (b) dose, RBD specific cellular responses were measured by IFN-γ and IL-4 ELISpot in PBMCs. Samples from 58 subjects and 18 subjects from ARVAC CG 25 µg and 50 µg cohorts were analyzed. Shown are spot-forming units (SFU) per 1 × 106 PBMCs producing IFN-γ and IL-4 after stimulation with-RBD peptide pool from samples with viable cells: N = 55 for IFN-γ and N = 51 for IL-4 in ARVAC CG 25 µg group and N = 18 for IFN-γ and N = 14 for IL-4 in ARVAC CG 50 µg group. Each point represents the result from a subject. Bars indicate the mean, and error bars the SEM. Statistical analysis (d1 vs. d28) was performed by the two tailed Wilcoxon matched pairs signed rank test. a IFN-γ SFU d1 vs. d28: P = 0.000003; IL-4 SFU d1 vs. d28: P = 0.00002; (b) IFN-γ SFU d1 vs. d28: P = 0.0155; IL-4 SFU d1 vs. d28: P > 0.05.